1


Board -2024 -Mtg -02 -Doc 01d

Report to the Board
6-7 June 2024

Subject No -Objection Consent Decisions
Agenda item 01 d
Category For Information


Since the December 2023 B oard meeting, seven decisions have been circulated
electronically for approval by no -objection consent in line with Section s 11 and 12 of
the Board and Board Committee Operating Procedures.
1) On 8 January 2024 , Board Members were invited to consider approv al of the
appointment of an Alternate Board Member and an Audit and Finance
Committee Member .

No objections were received prior to the end of 18 January 2024 and the following
decision was therefore entered into the record:

In accordance with Section 11.3 of the Board and Board Committee Operating
Procedures, on a no -objection basis, the Gavi Alliance Board:

a) Appointed George Laryea -Adjea as Alternate Board Member representing
UNICEF, effective immediately and until his successor is appointed ; and

b) Appointed Onei Uetela (Alternate Board Member) to the Audit and Finance
Committee, effective immediately and until 31 December 2025 .


2) On 16 February 2024, Board Members were invited to consider approv al of the
European Investment Bank Letter of Credi Facility .

No objections were received prior to the end of 28 February 2024 and the following
decision was therefore entered into the record:

In accordance with Section 1 2.2 of the Board and Board Committee Operating
Procedures, on a no -objection basis, the Gavi Alliance Board:

Approved the activation of the European Investment Bank Letter of Credit Facility
in one or more transactions up to the full value of US$ 320 million for market
shaping transactions, which would be approved by the Market -Sensitive Decisions
Committee.

DOCUMENT ADMINISTRATION
VERSION
NUMBER
APPROVAL PROCESS DATE
1.0 Prepared by: Ethics , Risk and Compliance 19 March 2024
Reviewed by: Senior Leadership Team (SLT) Q2
Reviewed by: Audit and Finance Committee 30 May 2024
Doc 01e - Annex A
1. Purpose
1.1 In developing this Restrictive Measures Compliance Policy (hereinafter referred to as the
' Policy '), Gavi reaffirms its commitment to the mission of helping to save lives and
improving people's health. Our dedication extends to careful compliance with applicable
laws and regulations, donor commitments and ensuring that every action also aligns with
the ethical principles that guide our endeavors.
1.2 Gavi approaches compliance with the seriousness it deserves, understanding that while
restrictive measures are not intended to obstruct the provision of vaccines, promoting
health and other types of assistance, they do apply and necessitate thorough due
diligence. In navigating this regulatory landscape, we are conscious of the extensive array
of exceptions and licenses related to the restrictive measures in place and available to
balance the need to ensure delivery of life- saving vaccines and related activities.
1.3 This Policy provides guidance to enhance understanding and raise awareness among all
Gavi Staff, regarding their restrictive measures compliance responsibilities and how to
address the potential compliance risks they may encounter.
2. Principles
2.1 Commitment to operate ethically: Gavi is committed to upholding the highest standards
of ethical conduct, legal compliance, and social responsibility in its global operations. As
such, compliance with relevant restrictive measures is key to our mission and values.
2.2 Focus on Gavi’s mission: Gavi’s overarching focus will always be on providing health
support to those in need as defined in its mission and strategy . Compliance to restrictive
measures is an essential tool to ensure that the funds and activities conducted for global
health purposes and broader strengthening of health systems are not being diver ted.
Where there is potential disruption to fulfilling Gavi’s mission, we will seek necessary
exceptions and authori sations to ensure the provision of essential vaccines and related
support to countries without compromising these principles .
2.3 Risk based and principle -based approach: Gavi's approach to compliance with
restrictive measures is founded on a risk -based methodology, ensuring that our
compliance measures are proportionate, effective, and tailored to address potential risks.
In recognition of Gavi’s mission, we commit to avoiding unnecessary or excessive
restrictions that may impede the timely provision of vaccines and healt h system
infrastructure .
2. 4 Consistency and transparency: Gavi’s approach to restrictive measures compliance is
based on consistent application of measures across all activities and maintaining
transparency in dealings with third parties.
3. Definitions
3.1 Restrictive measures: a set of requirements arising from nationally -set, international or
UN- applied decisions (i. e., sanctions) that could restrict the provision of funds and
resources to designated entities or persons, as well as the broader restrictions on specific
business activities within particular economic sectors/territories .
Doc 01e - Annex A

1


Board -2024 -Mtg -02-Doc 01e

Report to the Board
6-7 June 2024

Subject Consent Agen da – as at 31 May 2024
Agenda item 01 e
Category For Decision

Section A : Introduction
Four recommendations are being presented to the Board under the Consent Agenda
for consideration. Detailed information on the items can be found in the relevant
Committee papers in a dedicated folder on BoardEffect at:
https://gavi.boardeffect.co.uk/workrooms/6459/resources/263982
Section B : Actions Requested of the Board
The Gavi Alliance Board is requested to consider the following recommendations from
the Gavi Alliance Governance Committee and the Gavi Alliance Audit and Finance
Committee .
Decision One – Board Committee Chair Appointments
Governance Committee recommendation to be shared with the Board after
Governance Committee meeting of 5 June 2024 .
Decision Two – Board and Committee Appointments
Governance Committee recommendation to be shared with the Board after
Governance Committee meeting of 5 June 2024 .
Decision Three – Appointment of Treasurer
Governance Committee recommendation to be shared with the Board after
Governance Committee meeting of 5 June 2024 .
Decision Four – Restrictive Measures Compliance Policy
The Gavi Alliance Audit and Finance Committee recommends to the Gavi Alliance
Board that it:

Approve the Restrictive Measures Comp liance Policy as set out in Annex A to Doc
01e.

Classified as Internal #
Gavi Alliance Board Workplan
Gavi Board Paper July-NovDecMar/Apr JuneNov/Dec Mar/Apr JuneNov/Dec Mar/Apr JuneNov/Dec
A.Strategy/Performance/Risk/MEL CEO's Report CEO's Report
DiscussionDiscussionDiscussion DiscussionDiscussion DiscussionDiscussion 2021-2025 Strategy Strategy, Programmes and Partnerships: Progress, Risks and Challenges Discussion DiscussionDiscussion Discussion Innovation TBD Information
Private Sector Engagement TBDInformationInformation
Civil Society and Community Engagement Approach TBD
Partners' Engagement Framework Strategy, Programmes and Partnerships: Progress, Risks and Challenges
Discussion DiscussionDiscussion DiscussionDiscussion DiscussionDiscussion Disease Surveillance and Diagnostics in Gavi 5.0 TBD
Risk and Asurance Report Risk and Assurance ReportDecisionDecisionDecisionDecision
2026-2030 Strategy TBD
Discussion DiscussionDiscussionDiscussion Funding Policy Review (Elegiblity, Transiation & Co-financing; Middle-Income Countries Approach; HSS Allocation Formula) TBDDecisionDecision
Health Systems strategy TBDDecision
Approach to Fragile, Conflict & Humanitarian Settings TBD
Discussion Measurement Framework (Targets & Indicators) TBDGuidanceDecisionDecision B.Vaccines & Sustainablity Typhoid TBD Pneumococcal AMC (Advance Market Commitment) TBD Vaccine Investment Strategy Vaccine Investment Strategy COVID-19 Vaccine Programme Update Country Programmes Delivery Update Information Gavi's role in Pandemic Prevention, Preparedness and Response TBD Day Zero Facility - First Response Fund TBDDecisionInformationInformationInformation African Vaccine Manufacturing Accelerator TBD DecisionInformationInformationInformation RSV Investment Case TBD Decision Market Shaping Strategy TBDGuidance
Decision C.Policy Transparency and Accountability Policy TBD Evaluation Policy TBD Donations Policy TBD GuidanceDecision D.Country Programmes
Nigeria TBD
Information
PNG TBD
Information
Strategic Partnership with India Strategic Partnerships with India
Fiduciary risk assurance and financial management capacity building Fiduciary risk assurance and financial management capacity building E.
Finance/Audit & Investigations Annual Accounts Annual Financial Report DecisionDecisionDecision Financial Forecast Financial Update, including forecastDecisionDecisionDecision DecisionDecision DecisionDecision
Budget Financial Update, including forecastDecisionDecisionDecisionDecision
Programme Funding Policy Consent Agenda
Treasury Governance Policy Consent Agenda
Treasury Risk Management Policy Consent Agenda
Independent Auditor Selection and Evaluation Policy Consent Agenda
Audit & Investigations Report Audit & Investigations ReportInformationInformationInformationInformation F.Governance
Board Chair Appointment Consent Agenda DecisionDecision
Board Vice Chair Appointment Consent Agenda DecisionDecision
Committee Chair Appointments Consent AgendaDecisionDecision Decision
Board and Committee Appointments Consent AgendaDecisionDecision Decision
IRC Appointments Consent Agenda
CEO Appointment Consent Agenda Decision
Secretary Appointment Consent Agenda
Treasurer Appointment Consent Agenda
Appointment of MD A&I Consent Agenda
Amendments to Governance Documents (Statutes, By-Laws, Committee Charters) Consent Agenda
Evaluation Advisory Committee Terms or Reference Consent Agenda
IRC Terms of Reference Consent AgendaDecision
Audit & Investigations Terms of Reference Consent Agenda
G. Reporting
Committee Chair Reports Committee Chair and IFFIm Board reports InformationInformationInformation InformationInformation InformationInformation IFFIm Chair Reports Committee Chair and IFFIm Board reports InformationInformationInformation InformationInformation InformationInformation Replenishment/Resource Mobilisaton Resource Mobilisation Update Discussion
Discussion Collaboration with other organisations TBD InformationInformation HR Report Closed Session InformationInformationInformation InformationInformation InformationInformation Annual Report on Implementation of the Gender Policy Annex to Strategy paper InformationInformationInformationInformation Board and Committee minutes Annex to Board pack/On BE as additional materials Information
InformationInformation InformationInformation InformationInformation H. Technical Briefing Sessions/Deep Dives
Evaluations
Gavi Forecasting/Resource Allocation
Country Performance - High Impact Countries
Country Performance - Fragile Countries
2026 2027
Last updated - 23 May 2024
Next Board Meetings: 4-5 December 2024
9-10 April 2025 (Retreat)
25-26 June 2025
3-4 December 2025
2024
2025
Board-2024-Mtg-02-Doc 01f

1

Board -2024 -Mtg -02 -Doc 01a

Gavi Alliance Board Meeting
6-7 June 2024
Crowne Plaza Hotel, Geneva, Switzerland

Thursday 6 June: 08.30 -18.00 Board Meeting Day One
Friday 7 June: 09.00 -17. 00 Board Meeting Day Two

Quorum: 14
Declarations of Interest
Declarations
Section 5.5 of the Conflicts of Interest Policy for Governance Bodies states “Members involved
in decision -making processes on behalf of Gavi must take appropriate action to ensure
disclosure of Interests and Conflicts of Interest, and take the necessary action in respect
thereof.”
Section 6.2 of the Conflicts of Interest Policy for Governance Bodies further states, “The duty
to disclose [in 6.1 above] is a continuing obligation. This means that Members are obliged to
disclose any Interests and/or Conflict of Interest, whenever the M ember comes to know the
relevant matter.”
The following declarations were made by members of the Board on their most recent annual
statements .
Board members:
Member Organisational Interests Financial/Personal/Advisor Int/
Others










José Manuel Barroso,
Chair


















None









Hult – EF (Education First) (Visiting
Professor and Chair of Advisory
Council) ; Goldman Sachs (Chair of
International Advisors – from 1 April
2023) ; Princeton University z Princeton
School of Public Policy, LISD (Member
of the Advisory Council –from 01 April
2023) ; CAPRI, Center for AsiazPacific
Resilience and Innovation (Member of
the International Advisory Council from
01 April 2023) ; Catholic University of
Portugal (Visiting Professor at the
Institute of Political Studies and Director
of theCentre for European Studies) ;
The EUROPEAUM (Board Member) ;
WPLzWomen Political Leaders
(Advi sory Board Member) ; Jean Monnet
Foundation for Europe (Honorary
Committee Member) ; Global
Commission on Modern Slavery and

Board -202 3-Mtg -04 1
Minutes

Gavi Alliance Board Meeting
6-7 December 2023
Kempinski Hotel, Accra, Ghana

1. Chair’s report

1.1 Noting that the meeting had been duly convened and finding a quorum of
members present, the meeting commenced at 10.15 Accra time on
6 December 2023. Prof Jos é Manuel Barroso, Board Chair, chaired the
meeting.

1.2 The Chair welcomed new Board and Alternate members attending their first
Board meeting , namely: Sai Prasad, Soleh Ayubi, Karin Berlin and Leila
Gharagozloo Pakkala.

1.3 He recognised His Excellency Budi Gunadi Sadikin, Minister of Health of
Indonesia , as a Gavi Board member -elect . He also welcomed His Excellency
Rakan Khaled bin Doshaish , Assistant Deputy Minister for Health of Saudi
Arabia , and Jean Kaseya , Director General of the Africa Centres for Disease
Control and Prevention (CDC) .

1.4 The Chair noted that the Gavi Implementing Country Caucus met on 4
December 2023 during which the members welcomed Sarah Goulding, Vice
Chair, as a special guest and discussed how to strengthen the role of the
Caucus. He also noted the All Chairs Group (ACG) met on 3 December 2023
during which the members discussed the recommendations being brought
forward to the Board at this meeting.

1.5 He acknowledged the work of the Board Committees noting the CEO Search
Committee, Governance Committee, and Audit and Finance Committee had
met earlier in the week.

1.6 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack).

1.7 The Board noted its minutes from 26 -27 June 2023 (Doc 01b) and
11 September 2023 (Doc 01c) which were approved by no objection on
18 October 2023 and 2 November 2023 respectively . They also noted a number
of Board and Committee appointments that had been approved by no -objection
consent since the June 2023 Board meeting (Doc 01d).

1.8 The Chair referred to the consent agenda (Doc 01 e) where nine
recommendations were presented for consideration. At the request of the Chair,
Brenda Killen, Director, Governance and Secretary to the Board , presented the
consent agenda decisions . The Board noted the financial implications of one
consent agenda item and queried if decisions with material financial
implications should be approved outside the consent agenda process. The

1


Board -2024 -Mtg -02-Doc 00a


Gavi Alliance Board Meeting
6-7 June 202 4
Crowne Plaza Hotel , Geneva, Switzerland

Thursday 6 June: 08.30-18.00 (Board Meeting Day One)
Friday 7 June: 09.00 -17.00 (Board Meeting Day Two )

Quorum: 14

Document List

No. Document
00a Document list
00b Agenda
01a Declarations of interest
01b Minutes from 6-7 Dec ember 2023
01c Minutes from 11 January 2024
01d No Objection Consent Decisions
01e Consent Agenda
01f Workplan
02 CEO’s Report – To follow
03 Joint Alliance Update on Implementation of Gavi 5.1 Strategy, Programmes and
Partnerships
– No paper
03a Gavi 5.1 Strategy, Programmes and Partnerships : Progress, Risks and
Challenges
03b Joint Alliance Update on Country Programmes
04 Committee Chair and IFFIm Board reports – To follow
0 5 Gavi 6.0 – The Alliance’s Strategy 2026- 2030
06 Gavi 6.0 – Eligibility, Co -Financing and Transition Model, Middle- Income
Countries Approach and Health Systems Strategy – No paper
0 6a Future of Gavi’s Eligibility, Co
-financing and Transition Model and Middle-
Income Countries Approach
0 6b Health Systems Strategy

Board -202 4-Mtg -02-Doc 00b 1

Gavi Alliance Board Meeting
6-7 June 2024
Crowne Plaza Hotel , Geneva, Switzerland

Monday 3 June - Wednesday 5 June : Pre -Board meetings
Thursday 6 June : 08. 30 -18. 00 Board M eeting Day One
Friday 7 June : 0 9.00 -17.00 Board M eeting Day Two

Quorum: 14



A genda UPDATED
















Next Board Meeting : 4-5 December 2024
9-10 April 2025 (Board Retreat)
25-26 June 2025
3-4 December 2025

---
Brenda Killen , Director, Governance and Secretary to the Board, +41 22 909 6680, bkillen@gavi.org
Joanne Goetz , Head, Governance, +41 22 909 6544, jgoetz@gavi.org
Please note that the Board meeting will be recorded. This recording will be used as an aid to minute the
meeting. A transcription of the full proceedings will not normally be made. Should a transcription be made it
will be used only as an aid to minute the meeting.

gavi.org
REVIEW OF DECISIONS
BOARD MEETING
6 -7 June 2024, Geneva, Switzerland
Decision 1: Consent Agenda: Board Committee Chair
Appointment
2 Board Meeting, 6 -7 June 2024
The Gavi Alliance Board :
a) Appointed David Sidwell as an Unaffiliated Board Member in the seat currently held by
Naguib Kheraj, effective 1 August 2024 and until 31 July 2027 ; and
b) Appointed the following as Chair of the Audit and Finance Committee effective 1 August
2024 :
• David Sidwell (Board Member) until 31 December 2025

gavi.org
INNOVATIVE DEVELOPMENT INSTRUMENTS: DAY ZERO
FINANCING FACILITY – FIRST RESPONSE FUND AND
AFRICAN VACCINE MANUFACTURING ACCELERATOR (AVMA)
BOARD MEETING
Augustin Flory
6 -7 June 2024, Geneva, Switzerland
AVMA and FRF - core pillars of Gavi’s PPPR support
2 Board Meeting, 6 -7 June 2024
Africa remains vulnerable to supply insecurity
Africa accounts for 0.1% of global vaccine
production; 30+ projects, yet most will fail to reach
long -term viability
African manufacturers may be unviable in early
years Capital, labour and operating costs up to 50%
higher for new entrants in Africa, highlighting the need
for substantial downstream support, until economies
of scale are reached
AVMA would offer up to US$ 1 billion in support:
Priming the industry for long -term sustainability
De -risking investments and bolstering sustainability will
support Africa’s vaccine sovereignty, pandemic
preparedness whilst building a substantial biotech sector
The African Vaccine
Manufacturing Accelerator (AVMA)
First Response Fund (FRF)
Contingency funds are needed immediately
This could reduce deaths by up to 74%, and
economic costs by up to 95%
~50% gap in the estimated ~US$ 4 billion
required for rapid response financing for
outbreaks and pandemics
The First Response Fund pre -positions up to
US$ 500 million of at -risk surge financing -
available within the first 50 days of an
emergency, for vaccine procurement and other
urgent uses in core Gavi -eligible countries. The
Fund complements other Pandemic Prevention
Preparedness and Response (PPPR) financing
mechanisms in the global architecture
1
2

gavi.org
UPDATE ON COLLABORATION WITH OTHER
ORGANISATIONS
BOARD MEETING
Hope Johnson
Thabani Maphosa
6-7 June 2024, Geneva, Switzerland
2 Board Meeting, 6-7 June 2024
Keeping countries and communities central to our
collaboration
Guiding
Principles • Country led and demand driven
• Differentiated approach, leveraging the strengths of each Global Health Institution (GHI)
• Consideration for operating modalities of each GHI
High Impact
Workstreams • Malaria
• Health Systems Strengthening
• Country Engagement
Existing
collaboration • Investments and programming
• Legal, Audit & Investigation, Evaluations
• Resource mobilisation, communication, advocacy
Aligned
Communication • Consistent communication across Boards and Committees
• Clear narrative and strategic messaging to highlight distinct roles,
complementarities and impact
+ Enabling Functions (Gavi -Global Fund)

gavi.org
ROAD TO REPLENISHMENT
BOARD MEETING
Marie -Ange Saraka -Yao
6 -7 June 2024, Geneva, Switzerland
Protecting our future
Powered by
a unique and
innovative
model
Protecting
the World
Protecting
People
Protecting
Communities
Driven by
sustainability
• The African Vaccine Market Accelerator will build
resilience and support vaccine sovereignty
• Global health security preventing outbreaks and largest
investment in stockpiles against killer diseases like Ebola,
cholera and yellow fever
• >50% of Gavi’s vaccines will help countries adapt to the
threats of climate change and Anti -Microbial Resistance
• The widest portfolio in Gavi’s history with 24
life -saving vaccines for this generation of
children to be the most protected ever
• >100 million young women and girls
protected against cervical cancer , saving
1.5 million lives
• >50 million children will receive the new
malaria vaccine
• Gavi will facilitate 1.4 billion individual
contact points between families and
health services
• Gavi will strengthen health systems and
reach more women and zero -dose
children
• Over the next 5 years countries will fund
a record percentage of the costs of their
vaccines, contributing >US$ 4 billion
• By 2030, one in three of the 73 lower -
income countries originally supported by
Gavi will be fully funding their own
vaccine programmes
• Gavi will use its market power to pull
innovation form manufacturers
whilst reducing vaccine prices
across 50% of its portfolio
• Operational costs will stay lean: 97
cents of every $1 will go on buying
or delivering vaccines
* All numbers are provisional at this stage and will be
confirmed once Gavi 6.0 one -pager document is approved
2 Board Meeting, 6 -7 June 2024